ArticleBMJ global health2026
Evaluation of the first malaria vaccine introduction: ongoing learning opportunities during the introduction into routine immunisation in Cameroon.
Article in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessing the impact of routine malaria vaccination on total disease burden in Cameroon: a nationwide difference‑in‑differences analysis using health district surveillance data (2023-2025).Tropical diseases, travel medicine and vaccines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCameroon is the first country to introduce malaria vaccine (MV) into routine immunisation, following the pilot programme. The vaccine was introduced in 42 health districts across all 10 regions, with plans to scale up in additional districts in future. A mini-postintroduction evaluation (mini-PIE) was conducted to rapidly review the MV programme, make improvements and inform future strategies.
methodsA programme evaluation was conducted using desk review and field data collection with standardised interviews of immunisation staff and caregivers. A facilitated discussion was then conducted with key immunisation and malaria staff and partners using WHO intra-action review methodology.
resultsThe desk review found that completeness of monthly reports exceeded 95% in all regions in April 2024 except North-West and Adamawa (87%). Only 56% of eligible children received their first dose; however, coverage of the second and third doses was 31% and 28%, respectively. All 10 regions had high drop-out rates. Based on field data collection, 8 of 10 health facilities received communications materials for community awareness. Among caregivers interviewed, 88% (42/48) were aware of MV introduction (MVI); 60% (29/48) were informed by health workers and 81% (39/48) cited vaccine protection as the main reason to vaccinate children. 60% (29/48) knew the importance of continuing to use long-lasting insecticidal nets after malaria vaccination. During the facilitated discussion, 65% (n=37) of participants totally agreed that the mini-PIE methodology used was an effective way to identify challenges and lessons learnt.
conclusionsCameroon's MVI was largely successful, despite vaccine misinformation, demonstrating the importance of community dialogue and engagement in successful vaccine introduction. The mini-PIE methodology is recommended for other countries to adopt 4-6 months after introduction, including field work tailored to country needs and thorough desk review of key indicators conducted in advance to inform the facilitated discussion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.